Crunch Time For Glenmark’s US Innovation Arm, Founding CEO To Exit

 
• By Anju Ghangurde

Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.

challenge
Crucial Year Ahead For Ichnos To Navigate • Source: Alamy

More from Business

More from Scrip